

CURRICULUM VITAE

Date Prepared: June 27, 2007

Name (complete with degrees): Annick Desjardins, MD, FRCPC

Primary academic appointment: Associate in Medicine

Primary academic department (not DUAP): Neurology

Secondary appointment (if any) - (department): Surgery

Present academic rank and title (if any): Associate in Medicine
Duke University Medical Center

Date and rank of first Duke Faculty appointment: Associate in Medicine (August 2005)

Medical Licensure: North Carolina License

Date of License (Month/Day/Year): July 15, 2005

Specialty certification(s) and dates (Month/Day/Year): NA

Education:

	<u>Institution</u>	<u>Date (Year)</u>	<u>Degree</u>
High School	Polyvalente Paul-Hubert, PQ, Canada	1992	
College	Cegep de Rimouski, PQ, Canada	1994	DEC
Graduate or Professional School	Medical School, Universite de Sherbrooke, PQ, Canada	1998	MD

Scholarly Societies (Alpha Omega Alpha, Sigma Xi, Phi Beta Kappa; etc.): N/A

Professional Training and Academic Career (chronologically, beginning with first postgraduate position):

<u>Institution</u>	<u>Position/Title</u>	<u>Dates</u>
Universite de Sherbrooke PQ, Canada	Residency in adult neurology	July 1998- June 2003
Duke University Medical Center NC, USA	Fellowship in Neuro-Oncology	July 2003- July 2005

PUBLICATIONS:

Refereed Journals:

1. Fortin D, Salame JA, **Desjardins A**, Benko A. Technical Modification in the Intracarotid Chemotherapy and Osmotic Blood-Brain Barrier Disruption Procedure to Prevent the Relapse of Carboplatin-Induced Orbital Pseudotumor. *Am J Neuroradiol*, 25(5):830–834, 2004.
2. Fortin D, **Desjardins A**, Benko A, Niyonsega T, Boudrias M. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors. *Cancer*, 103(12):2606-2615, 2005.
3. Quinn JA, **Desjardins A**, Weingart J, Brem H, Dolan ME, Delaney SM, Vredenburgh J, Rich J, Friedman AH, Reardon DA, Sampson JH, Pegg AE, Moschel RC, Birch R, McLendon RE, Provenzale JM, Gururangan S, Dancey JE, Maxwell J, Yourt-Uhlig S, Herndon JE 2nd, Bigner DD, Friedman HS. Phase 1 trial of temozolomide plus 06-benzylguanine for patients with recurrent or progressive malignant glioma. *J Clin Onco*, 23(28): 7178-7187, 2005.
4. **Desjardins A.**, Rich JN, Quinn JA, Vredenburgh J, Gururangan S, Sathornsumetee S, Reardon DA, Friedman AH, Bigner DD, Friedman HS. Chemotherapy and novel therapeutic approaches in malignant glioma. *Front. Biosci.*10:2645-2668, 2005.
5. Reardon DA, Egorin MJ, Quinn JA, Rich JN, Gururangan S, Vredenburgh JJ, **Desjardins A**, Sathornsumetee S, Provenzale JM, Tourt-Uhlig S, Herndon 2nd JE, Dowell JM, McLendon RE, Lagattuta TF, Kicielinski KP, Dresemann G, Salvado AJ, Friedman AH, Friedman HS. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. *J Clin Oncol*, 23(26):9359-9368, 2005.
6. Reardon DA, Quinn JA, Rich JN, **Desjardins A**, Vredenburgh J, Gururangan S, Sathornsumetee S, Badrudoja M, McLendon R, Provenzale J, Herndon 2nd JE, Dowell JM, Burkat JL, Newton HB, Friedman AH, Friedman HS. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. *Cancer* 104:1478-1486, 200.
7. Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HA, Herndon 2nd JE, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Vredenburgh JJ, **Desjardins A**, Gururangan S, Badrudoja M, Dowell JM, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD. Salvage radioimmunotherapy with murine ¹³¹I-labeled anti-tenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: Phase II study results. *J Clin Oncol*, 24(1):115-122, 2006.
8. Reardon DA, Quinn JA, Vredenburgh JJ, Gururangan S, Friedman AH, **Desjardins A**, Sathornsumetee S, Herndon 2nd JE, Dowell JM, McLendon RE, Provenzale JM, Sampson JH, Smith RP, Swaisland AJ, Ochs JS, Lyons P, Tourt-Uhlig S, Bigner DD, Friedman HS, Rich JN. Phase I trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. *Clin Ca Res*, 12(3):860-868, 2006.
9. Reardon DA, Quinn JA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, McLendon RE, Pegram CN, Provenzale JM, Dowell JM, Rich JN, Vredenburgh JJ, **Desjardins A**,

Sampson JH, Gururangan S, Wong TZ, Badruddoja MA, Zhao XG, Bigner DD, Zalutsky MR. Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: Phase I trial results. *J Nucl Med*, 47(6):912-918, 2006.

10. Badruddoja MA, Penne K, **Desjardins A**, Reardon DA, Rich JN, Quinn J, Sathornsumetee S, Friedman A, Bigner DD, Herndon II JE, Dowell J, Sznol M, Cahill A, Friedman HS, Vredenburgh JJ. Phase II study of cloretazine for the treatment of adults with recurrent glioblastoma multiforme. *Neuro-Oncology*, 9(1):70-74, 2007.
11. Vredenburgh J, **Desjardins A**, Herndon 2nd JE, Dowell J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS. Phase II trial of Bevacizumab and Irinotecan in recurrent malignant glioma *Clin Ca Res* 13(4):1253-1259, 2007.
12. Sathornsumetee S, **Desjardins A**, Reardon DA, Rich JN, Vredenburgh JJ. Neurofibromatosis type 2. *Neurology* 68(13):E14, 2007.
13. Gururangan S, Fisher MJ, Allen JC, Herndon 2nd JE, Quinn JA, Reardon DA, Vredenburgh JJ, **Desjardins A**, Phillips PC, Watral MA, Krauser JM, Friedman AH, Friedman HS. Temozolomide in children with progressive low-grade glioma. *Neuro-Oncol* 9(2):161-168, 2007.
14. **Desjardins A**, Quinn JA, Vredenburgh JJ, Sathornsumetee S, Friedman AH, Herndon 2nd JE, McLendon RE, Provenzale JM, Rich JN, Sampson JH, Gururangan S, Dowell JM, Salvado A, Friedman HS, Reardon DA. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. *J Neurooncol*. 83(1):53-60, 2007.
15. Sathornsumetee S, Reardon DA, **Desjardins A**, Quinn JA, Vredenburgh JJ, Rich JN. Molecularly targeted therapy for malignant glioma. *Cancer* 110(1):13-24, 2007.

Non-Refereed Publications:

1. **Desjardins A**, Rich J. Tyrosine Kinase Inhibitor Therapies in Malignant Glioma Therapy .Departments of Surgery*, Medicine†, and Department of Neurobiology‡, Duke University Medical Center, Durham, NC Hospital Pharmacy Europe; November/December 2005.

In Press:

1. **Desjardins A**, Reardon DA. Current Therapies and Future Directions in the Treatment of Malignant Glioma. *Future Drugs*, In Press, 2007.
2. Reardon DA, Zalutsky MR, Akabani G, Coleman RE, Friedman AH, Herndon 2nd JE, McLendon RE, Pegram CN, Quinn JA, Rich JN, Vredenburgh JJ, **Desjardins A**, Boulton A, Raynor RH, Wong TZ, Zhao XG, Friedman HS, Bigner DD. A pilot study: 131I-anti-tenascin monoclonal antibody 81C6 to deliver a 44 Gy resection cavity boost. *Neuro-Oncology*, In Press, 2007
3. Vredenburgh JJ, **Desjardins A**, Herndon 2nd JE, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS. Bevacizumab and Irinotecan: An Active Regimen against Recurrent Glioblastoma Multiforme. *J Clin Oncol*, In Press, 2007.

Submitted for Publication:

1. **Desjardins A**, Gururangan S, Cavazos C, Herndon 2nd JE, Tourt-Uhlig S, Rich J.N, Quinn J.A, Reardon DA, Vredenburgh J, Friedman AH, Friedman HS. Phase II study of low-dose carboplatin chemotherapy in adults with progressive low-grade gliomas. Submitted, 2006.

Selected Abstracts – Oral presentation:

1. **Desjardins A**, Boudrias M, Fortin D. Osmotic blood-brain barrier disruption to enhance chemotherapy delivery in the treatment of brain tumors: The Sherbrooke experience. Abstract #A-07. Can J Neurol Sci. 29(Suppl 1):S9, 2002.
2. **Desjardins A**, Goudar R, Keir S, Hjelmeland M, Traxler P, Lane H, Wang XF, Bigner DD, Friedman HS, Rich, JN. Combinatorial benefit of inhibition of epidermal growth factor receptor and mammalian target of rapamycin (mTOR) in the treatment of malignant glioma xenografts. Abstract #I-04. Can J Neurol Sci. 31(Suppl 1):S23, 2004.
3. **Desjardins A**, Vredenburgh J, Quinn JA, Reardon D, Rich JN, Friedman HS. Phase I trial of adults with primary malignant glioma with Irinotecan (CPT-11) plus temozolomide (Temodar). Abstract #TA-17. Neuro-Oncology, 6(4):373, 2004.
4. Quinn JA, **Desjardins A**, Vredenburgh J, Reardon D, Rich J, Friedman HS. Phase II Trial of temozolomide (Temodar) plus O6-Benzylguanine (O6-BG) in the treatment of patients with Temodar-resistant malignant glioma. Abstract #TA45. Neuro-Oncology, 6(4):380, 2004.
5. **Desjardins A**, Quinn J, Reardon D, Rich J, Sathornsumetee S, Vredenburgh J, Walker A, Tourt-Uhlig S, Bigner D, Friedman H. Temzolomide (TMZ) with O6-benzylguanine (BG) for TMZ-resistant malignant glioma: a phase II trial. Abstract #119. Neuro-Oncology, 7(3):312, 2005.
6. Reardon DA, Quinn J, Rich J, Vredenburgh J, **Desjardins A**, Sathornsumetee S, Salvado A, Nikolova Z, Bigner D, Friedman H. Imatinib mesylate (Gleevec) plus hydroxyurea: an effective regimen in the treatment of recurrent malignant glioma: Phase 2 study results. Abstract #35. Neuro-Oncology, 7(3):291, 2005.
7. Friedman HS, Quinn J, Rich J, Vredenburgh J, **Desjardins A**, Sathornsumetee S, Salvado A, Nikolova Z, Bigner D, Reardon D. Imatinib mesylate (gleevec) plus hydroxyurea is an effective regimen in the treatment of recurrent malignant glioma. Phase 2 study results. Abstract #1515. J Clin Oncol. 23:117a, 2005.
8. Badruddoja MA, Penne K, **Desjardins A**, Reardon AD, Rich JN, Quinn J, Sznol M, Cahill A, Friedman HS, Vredenburgh J. Phase II study of VNP40101M for adults with recurrent malignant glioma. Abstract #3128. J Clin Oncol. 23:223s, 2005
9. Vredenburgh J, **Desjardins A**, Herndon II JE, Quinn J, Rich J, Sathornsumetee S, Friedman HS. Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas. Abstract # 1506. J Clin Oncol. 24:59s, 2006.
10. Reardon D, Akabani G, Friedman H, Herndon J, McLendon R, Quinn J, Rich J, Vredenburgh J, **Desjardins A**, Sampson J, Gururangan S, Kirkpatrick J, Wong T, Dowell J, Dunn R, Sathornsumetee S, Boulton S, Coleman R, Zalutsky M, Bigner D. Patient-specific murine ¹³¹I-labeled anti-tenascin

monoclonal antibody 81C6 radioimmunotherapy for delivering a 44-GY boost to the resection cavity periphery of patients with newly diagnosed primary malignant brain tumors: A feasibility pilot study. Abstract #RO-23. Neuro-Oncology, 8(4):489, 2006.

11. Vredenburgh J, **Desjardins A**, Herndon 2nd JE, Reardon D, Quinn J, Sathornsumetee S, Gururangan S, Friedman A, Bigner D, Friedman H. Bevacizumab and irinotecan is an effective treatment for malignant glioma. Abstract #TA-64. Neuro-Oncology, 8(4):454, 2006.
12. Goli KJ, **Desjardins A**, Herndon 2nd JE, Rich JN, Reardon DA, Quinn JA, Sathornsumetee S, Bota DA, Friedman HS, Vredenburgh JJ. Phase II trial of bevacizumab and irinotecan in the treatment of malignant gliomas. Abstract #2003, J Clin Oncol, 25:18s, 2007.

Selected Abstracts :

1. **Desjardins A**, Evoy, F. Contralateral carotid artery dissection after thrombolytic therapy for an acute stroke. Can J Neurol Sci. 28(Suppl 2), 2001.
2. **Desjardins A**, Salame J, Evoy F, Fortin D, Benko A. Orbital pseudotumor after intraarterial carboplatin: Report of three cases. Abstract #P-108. Can J Neurol Sci. 30(Suppl 2):S65, 2003.
3. Adams R, **Desjardins A**, Gallez A, Fortin DA. A Modification to an Animal Model for Osmotic Blood-Brain Barrier Disruption Eliminating Hemodynamic Effects Produced by Anaesthetic Agents. Abstract #P-116. Can J Neurol Sci. 30(Suppl 2):S67, 2003.
4. **Desjardins A**, Quinn JA, Reardon DA, Rich J, Vredenburgh J, Efird C, and Friedman HS. Phase II study of thalidomide and daily Cyclophosphamide for adults with malignant glioma. Abstract #1554. J Clin Oncol. 22:120s, 2004.
5. **Desjardins A**, Hjelmeland M, Herbstreith M, Sathornsumetee S, Hjelmeland A, Laping N, Bigner D, Wang X, Rich J. Inhibition of human glioma xenograft malignant phenotype by a small molecule transforming growth factor-beta-receptor antagonist, SB431542. Abstract #P-121. Can J Neurol Sci, 31(Suppl 1):S61, 2004.
6. **Desjardins A**, Shafman T, Reardon D, Akabani G, Friedman A, Friedman H, Sampson J, Wong T, Zhao XG, Zalutsky, Biger, D. Phase II trial of 131-iodine labeled murine antitenascin monoclonal antibody 81C6 (¹³¹I-m81C6) administered to deliver a targeted radiation boost dose of 44Gy to the resection cavity perimeter of patients with newly diagnosed malignant brain tumors: Preliminary results. Abstract #P-120. Can J Neurol Sci, 31(Suppl 1):S61, 2004.
7. **Desjardins A**, Vredenburgh J, Quinn JA, Reardon D, Rich J, Friedman HS. Phase II Study of thalidomide and daily low-dose cyclophosphamide for adults with anaplastic gliomas. Abstract #TA-16. Neuro-Oncology, 6(4):373, 2004.
8. Quinn JA, **Desjardins A**, Vredenburgh J, Reardon D, Rich J, Friedman HS. Phase I trial of temozolomide (Temodar) plus irinotecan (CPT-11) plus O6-Benzylguaninge (O6-BG) in the treatment of recurrent or progressive cerebral anaplastic gliomas. Abstract #TA-44. Neuro-Oncology, 6(4):380, 2004.
9. Badruddoja MA, Reardon DA, Vredenburgh JJ, Quinn JA, Rich JN, **Desjardins A**, Friedman A, Walker A, Bailey P, Jex R, Friedman HS. Phase II upfront CPT-11 plus celecoxib for adults with glioblastoma multiforme. Abstract TA-01. Neuro-Oncology, 6(4):369, 2004.

10. Reardon D, Friedman A, Herndon J, Quinn J, Rich J, Vredenburgh J, Badruddoja M, **Desjardins A**, Sampson J, Gururangan S, Dowell J, Affronti M, Allen D, Jackson S, Zeigler K, Silverman S, Tourt-Uhlig S, Silverman S, Salvado A, Nikolova Z, Bigner DD, Friedman HS. Phase II trial of imatinib mesylate plus hydroxyurea in the treatment of patients with malignant glioma. Abstract TA-47. Neuro-Oncology, 6:381, 2004.
11. **Desjardins A**, Quinn J, Reardon D, Rich J, Vredenburgh J, Sathornsumetee S, Walker A, Tourt-Uhlig S, Bigner D, Friedman H. Temozolomide (TMZ) with O⁶-benzylguanine (BG) plus CPT-11 in the treatment of recurrent malignant glioma: a phase I trial. Abstract #152. Neuro-Oncology, 7(3):152, 2005.
12. **Desjardins A**, Vredenburgh J, Badruddoja M, Quinn J, Reardon D, Rich J, Sathornsumetee S, Penne K, Bigner D, Friedman H. Phase II study of cloretazine for the treatment of adults with recurrent malignant glioma. Abstract #141. Neuro-Oncology, 7(3):317, 2005.
13. Reardon DA, Rich J, Quinn J, Vredenburgh J, **Desjardins A**, Sathornsumetee S, Gururangan S, Lyons P, Bigner D, Friedman H. Phase I study results of gefitinib (Iressa; ZD1839) plus rapamycin in the treatment of patients with recurrent malignant glioma. Abstract #119. Neuro-Oncology, 7(3):312, 2005.
14. Friedman HS, Quinn J, Rich J, Vredenburgh J, **Desjardins A**, Sathornsumetee S, Salvado A, Nikolova Z, Bigner D, Reardon D. Efficacy of imatinib mesylate plus hydroxyurea regimen in the treatment of recurrent malignant glioma: Phase II study results. Abstract #1515. J Clin Oncol, 23:116s, 2005.
15. Sathornsumetee S, Reardon DA, Quinn J, Rich JN, Vredenburgh J, **Desjardins A**, Gururangan P, Lyons P, Salvado A, Friedman HS. A Phase I Dose Escalation Study of Imatinib Mesylate (Gleevec) Plus Standard-Dosed Temozolomide in the Treatment of Patients with Malignant Glioma. Abstract #1540. J Clin Oncol. 23:124s, 2005.
16. Rich JN, Reardon DA, Quinn JA, Vredenburgh JJ, **Desjardins A**, Sathornsumetee S, Gururangan S, Lyons P, Bigner DD, Friedman HS. A phase I trial of gefitinib (Iressa; ZD1839) plus rapamycin for patients with recurrent malignant glioma. Abstract #1565. J Clin Oncol. 23:130s, 2005.
17. **Desjardins A**, Reardon D, Quinn J, Rich J, Vredenburgh J, Sathornsumetee S, Gururangan S, Salvado A, Friedman H. Phase II trial of imatinib mesylate (Gleevec®) and hydroxyurea for grade III malignant gliomas. Abstract # 1573. J Clin Oncol. 24:76s, 2006.
18. Vredenburgh JJ, Bohlin C, Reardon DA, **Desjardins A**, Quinn J, Rich J, Sathornsumetee S, Marks LB, Friedman AH, Friedman HS. Tinzaparin prophylaxis against thromboembolic complications in brain tumor patients. Abstract # 1539. J Clin Oncol. 24:67s, 2006.
19. Sathornsumetee S, Reardon DA, Quinn JA, Rich JN, Vredenburgh JJ, **Desjardins A**, Gururangan S, Egorin M, Salvado A, Friedman HS. An update on phase I study of dose escalating imatinib mesylate plus standard dosed temozolomide for the treatment of patients with malignant glioma. Abstract # 1560. J Clin Oncol. 24:72s, 2006.
20. Quinn JA, Vredenburgh JJ, Rich JN, Reardon DA, **Desjardins A**, Gururangan S, Friedman AH, Lavin K, Sathornsumetee S, Threatt S, Friedman HS. Phase II trial of Gliadel plus O⁶-benzylguanine (O⁶-BG) for patients with recurrent glioblastoma multiforme. Abstract # 1568. J Clin Oncol. 24:74s, 2006.

21. Reardon DA, Quinn JA, Rich JN, Vredenburgh JJ, **Desjardins A**, Sathornsumetee S, Gururangan S, Egorin MJ, Salvado A, Friedman HS. A phase I trial of imatinib, hydroxyurea and RAD001 for patients with recurrent malignant glioma. Abstract # 1580. J Clin Oncol. 24:77s, 2006.
22. Heery CR, **Desjardins A**, Quinn JA, Rich JN, Gururangan S, Vredenburgh JJ, Friedman AH, Reardon DA, Friedman HS. Acute toxicity analysis of patients receiving surgery, Gliadel wafer implantation, and postoperative daily temozolomide with radiation therapy for primary high grade glioma. Publication # 11504. J Clin Oncol. 24:593s, 2006.
23. Kirkpatrick J, **Desjardins A**, Vredenburgh JJ, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S., Friedman AH, Friedman HS, Reardon DA. Publication # 11522. J Clin Oncol. 24:594s, 2006.
24. Affronti ML, Dowell JM, Herndon 2nd JE, Cahill J, Rich JN, Quinn JA, Reardon DA, Vredenburgh JJ, **Desjardins A**, Gururangan S, Friedman HS. Overall survival of primary glioblastoma (GBM) patients receiving radiation and concurrent temozolomide followed by rotational multi-agent chemotherapy. Abstract #TA-01. Neuro-Oncology, 8(4):437, 2006.
25. **Desjardins A**, Vredenburgh J, Quinn J, Rich J, Sathornsumetee S, Gururangan S, Friedman A, Reardon D, Friedman H. Combination of bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and chemotherapy for recurrent malignant glioma patients: Series of cases. Abstract TA-12. Poster presentation, Society for Neuro-Oncology Eleventh Annual Meeting, Orlando, Florida, November 15-19, 2006. Neuro-Oncology, 440, 2006.
26. **Desjardins A**, Vredenburgh J, Quinn J, Rich J, Sathornsumetee S, Friedman A, Reardon D, Friedman H. Combination of bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and temozolomide or irinotecan as an upfront treatment in patients with malignant glioma: Study of cases. Abstract #TA-13. Neuro-Oncology, 8(4):440, 2006.
27. **Desjardins A**, Quinn JA, Rich JN, Vredenburgh JJ, Sathornsumetee S, Gururangan S, Friedman AH, Berg W, Egorin MJ, Salvado A, Friedman HS, Reardon DA. A phase I trial of imatinib (Gleevec), hydroxyurea and RAD001 for patients with recurrent malignant glioma. Abstract #TA-14. Neuro-Oncology, 8(4):441, 2006.
28. Quinn JA, **Desjardins A**, Rich JN, Vredenburgh JJ, Reardon DA, Gururangan S, Sathornsumetee S, Walker A, Lavin KN, Birch R, Friedman AH, Friedman HS. Phase I trial of temodar plus O⁶-Benzylguanine 5-day regimen for patients with progressive glioblastoma multiforme. Abstract #TA-48. Neuro-Oncology, 8(4):450, 2006.
29. Sathornsumetee S, Rich JN, Vredenburgh JJ, **Desjardins A**, Quinn JA, Gururangan S, Friedman AH, Egorin MJ, Salvado A, Friedman HS, Reardon DA. Phase I trial of temozolomide plus dose-escalating imatinib mesylate for patients with malignant glioma. Abstract #TA-50. Neuro-Oncology, 8(4):451, 2006.
30. Sathornsumetee S, Rich JN, Vredenburgh JJ, **Desjardins A**, Quinn JA, Gururangan S, Egorin MJ, Salvado AJ, Friedman HS, Reardon DA. Phase I trial of imatinib mesylate, hydroxyurea and vatalanib for patients with recurrent glioblastoma multiforme (GBM). Abstract #2027, J Clin Oncol 25:81s, 2007.
31. **Desjardins A**, Barboriak DP, Herndon 2nd JE, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Friedman HS, Vredenburgh JJ. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) evaluation in glioblastoma (GBM) patients treated with bevacizumab (BEV) and irinotecan (CPT-11). Abstract #2029, J Clin Oncol 25:82s, 2007.

32. Quinn JA, Vredenburgh JJ, Rich JN, Reardon DA, **Desjardins A**, Gururangan S, Friedman AH, Carter JH, Threatt S, Freidman HS. Phase II trial of Gliadel plus O⁶-benzylguanic (O⁶-BG) for patients with recurrent glioblastoma multiforme. Abstract #2036, J Clin Oncol 25:84s, 2007.
33. Bota DA, **Desjardins A**, Quinn JA, Rich JN, Vredenburgh JJ, Sathornsumetee S, Goli K, Salvado A, Friedman HS, Reardon DA. Phase II trial of imatinib mesylate and hydroxyurea for adults with recurrent/progressive low-grade glioma. Abstract #2053, J Clin Oncol 25:88s, 2007.
34. Kirkpatrick J, **Desjardins A**, Quinn J, Rich J, Vredenburgh J, Sathornsumetee S, Gururangan S, Sidor C, Friedman H, Reardon D. Phase II open-label, safety, pharmacokinetic and efficacy study of 2-methoxyestradiol nanocrystal colloidal dispersion administered orally to patients with recurrent glioblastoma multiforme. Abstract #2065, J Clin Oncol 25:91s, 2007.
35. Affronti ML, Day JM, Herndon 2nd JE, Rich JN, Quinn JA, Reardon DA, Vredenburgh JJ, **Desjardins A**, McLendon RE, Friedman HS. Radiation and concurrent temozolomide followed by rational multi-agent chemotherapy for glioblastoma (GBM) patients. Abstract #2068, J Clin Oncol 25:92s, 2007.
36. Rich JN, Affronti ML, Day JM, Herndon 2nd JE, Quinn JA, Reardon DA, Vredenburgh JJ, **Desjardins A**, Friedman. Overall survival of primary glioblastoma (GBM) patients (pts) receiving Carmustine (BCNU) wafers followed by radiation (RT) and concurrent temozolomide (TMZ) plus rotational multi-agent chemotherapy. Abstract #2070, J Clin Oncol 25:92s, 2007.
37. Bohlin CW, Reardon DA, **Desjardins A**, Quinn JA, Rich JN, Bota DA, Goli K, Friedman HS, Vredenburgh JJ. Tinzaparin prophylaxis in brain tumor patients. Publication #12506, J Clin Oncol 25:605s, 2007.
38. Vredenburgh JJ, Bohlin CH, Reardon DA, **Desjardins A**, Quinn JA, Rich JN, Bota DA, Goli KJ, Friedman HS, Allen DH. Pilot study of dronabinol for adult patients with primary malignant gliomas. Publication #19607, J Clin Oncol 25:715s, 2007.

PROFESSIONAL AWARDS AND SPECIAL RECOGNITIONS:

- | | |
|---------------------|---|
| September 2001 | Quebec Neurological Association
Resident competition, 1 st place, \$1,500 prize
Clinical Research in Neuro-Oncology
Platform presentation |
| July 2006-July 2007 | SPORE* Career Development Award, \$50,000
Use of stem cells for the treatment of malignant gliomas.
<i>*Specialized Programs of Research Excellence</i> |
| March 2007 | Young Investigator Award, \$1,500 prize
Duke Comprehensive Cancer Center |

ORGANIZATIONS AND PARTICIPATION: (Offices held, committee assignments, etc.)

- | | |
|--------------|---------------------------------------|
| 1999-Ongoing | American Academy of Neurology |
| 2003-Ongoing | American Society of Clinical Oncology |

2003-Ongoing The Royal College of Physicians and Surgeons of Canada

2004-Ongoing Society of Neuro Oncology

TEACHING RESPONSIBILITIES INCLUDING CONTINUING EDUCATION:

September 2002 Basic Neuro-Sciences.
Twelve hour class for Students in Master Degree in Bioengineering.
Universite de Sherbrooke, Quebec, Canada

February-March 2003 Initiation to Neurological Sciences.
Nine weeks initiation for 1st year Medical Students to Neurological Sciences.
Universite de Sherbrooke, Quebec, Canada

July 2003-Ongoing Mentor to Medical Students and Undergraduate Students at the Preston Robert
Tisch Brain Tumor Center clinic.
Durham, NC

July 2003-Ongoing Neuroradiology training for all new clinical employees at the Preston Robert
Tisch Brain Tumor Center.
Durham, NC

June 2004 Translation of Transduction.
Presentation on malignant glioma molecular signaling at the Clinical
Neuroscience Grand Rounds.
Duke University Medical Center, Durham, NC

August 2005-Ongoing Involved in the CAPE* Program
Small group teaching of the neurological examination and MRI reading.
Year-round supervision of CAPE undergraduate students in the Brain Tumor
Center Clinic.
Duke University Medical Center, Durham, NC
**Collegiate Athlete Premedical Experience*

April 5, 2007 Diagnostic Day for the Master's in Oncology Nursing Students.
Teaching the neurological examination and MRI reading to nursing students.
School of Nursing, Duke University Medical Center, Durham, NC

JOURNAL REVIEWS:

August 2006- Present Reviewer for Cancer

CLINICAL RESEARCH EXPERIENCES:

A Phase I Trial of the Addition of the Farnesyl Transferase Inhibitor, SCH 66336, to TEMODAR[®] for patients with Grade 3 or 4 Malignant Gliomas.
Principal Investigator

Phase II Trial of Erlotinib Plus Hydroxyurea for Patients with Recurrent Malignant Glioblastoma Multiforme.
Principal Investigator

A Single-Center, Open-Label, Phase II, Safety and Efficacy Study of Panzem Nanocrystal Colloidal Dispersion Administered Orally in Combination with Protracted Oral Fixed-Dose Temozolomide to Patients with Recurrent Glioblastoma Multiforme.

Principal Investigator

A Phase II Trial of RAD001 in Patients with Recurrent Glioblastoma Multiforme.

Principal Investigator

Bevacizumab In Combination With Irinotecan For Malignant Gliomas

Co-Principal Investigator

Dynamic Contrast-enhanced Magnetic Resonance Imaging with Bevacizumab In Combination With Irinotecan For Malignant Gliomas

Co-Principal Investigator

As an Attending Physician at the Preston Robert Tisch Brain Tumor Center, every week, I see approximately 24 follow-up patients, three to four new patient consultations and review 20-30 outside MRIs. For each patient, the clinical status and tumor response is reviewed and a new treatment plan is developed. Approximately 20-30 studies are open for enrollment at any given time at the Preston Robert Tisch Brain tumor Center, two third of all the patients under my care are enrolled on the clinical trials available to the Preston Robert Tisch Brain Tumor Center.

I also attend the Protocol Development Meeting of the Preston Robert Tisch Brain Tumor center held every two weeks. Protocols in development are discussed with the team. Also, the enrollment and priority of ongoing protocols are discussed as a team.

Under the mentorship of David A Reardon, M.D., James J. Vredenburgh, M.D., and Henry S. Friedman, I maintain almost daily communication with multiple pharmaceutical collaborators concerning ongoing trials, protocols in development, and discussion of new trials.

AREAS OF RESEARCH INTERETS (basic and applied):

Clinical research for the treatment of primary malignant gliomas

Incorporation of hematopoietic stem cells in the treatment of primary malignant gliomas

CLINICAL ACTIVITY - Type of Practice and Estimate of Time Commitment:

Inpatient rounds: 2 months/year

Neuro-oncology Clinic: 1 day/week

Clinical Research: protocol preparation, protocol execution, and manuscripts: 80-85% time

Participation in Academic and Administrative Activities of the University and Medical Center:

Director of Clinical Operations for the Preston Robert Tisch Brain Tumor Center

- New clinic development
- Clinic scheduling
- Supervision of the mid-level providers and nurse clinicians (25 people)

Supervision of Neuro-Oncology fellows in the Neuro-Oncology Clinic, as well as with MRI reading.

Weekly supervision of medical students and undergraduate (premed) students in the Neuro-Oncology Clinic.

Mentor for the CAPE Program. Supervision in clinic and small group teaching.

Translational laboratory meeting of the Preston Robert Tisch Brain Tumor Center.

Protocol Development Meeting of the Preston Robert Tisch Brain Tumor Center.

Physician consultant for the Preston Robert Tisch Brain Tumor Center Quality of Life committee.

Member of the Task Force Team for the development of the new Brain Tumor Center Clinic (1K).